证券代码：002317 公告编号：2025-060 广东众生药业股份有限公司 广东众生药业股份有限公司（以下简称"公司"）股票（证券简称：众生药 业，证券代码：002317）于 2025 年 6 月 9 日及 6 月 10 日连续两个交易日内日收 盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规则》等有关规定， 属于股票交易异常波动的情况。 二、公司关注并核实相关情况 针对公司股票异常波动，公司董事会对公司、公司控股股东及实际控制人 就有关事项进行了核查，现就有关情况说明如下： 1、公司未发现前期披露的信息存在需要更正、补充之处； 关于公司股票交易异常波动的公告 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息； 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 3、公司目前经营情况正常，内外部经营环境未发生重大变化； 一、股票交易异常波动的情况介绍 4、公司、控股股东及实际控制人不存在关于公司的应披露而未披露的重大 事项，也不存在处于筹划阶段的重大事项； 公司董事会确认，公司目前没有任何根据《深圳证券交易 ...

Core Viewpoint - The stock of Zhongsheng Pharmaceutical (002317) experienced an abnormal trading fluctuation, with a cumulative closing price deviation exceeding 20% over two consecutive trading days on June 9 and June 10, 2025 [1] Clinical Trials - The company has received ethical approval for three Phase III clinical trials: RAY1225 injection for overweight/obese patients and two trials for Type 2 diabetes patients [1] - The progress of clinical trials, review and approval outcomes, and future market competition landscape for RAY1225 injection carry a degree of uncertainty [1] Market Uncertainty - There is uncertainty regarding whether the drug will be approved for market launch, the timing of such approval, and the subsequent production and sales conditions post-approval [1]

Market Overview - The A-share market showed a narrow range of consolidation on June 10, with the Shanghai Composite Index rising by 0.11% to 3403.52 points, while the Shenzhen Component Index fell by 0.23% and the ChiNext Index decreased by 0.36% [1] - The total trading volume for the A-share market reached 808.39 billion yuan [1] Monetary Policy - The People's Bank of China conducted a 7-day reverse repurchase operation of 198.6 billion yuan at a fixed rate of 1.40%, with a total bid amount matching the operation amount [2] - A net withdrawal of 255.9 billion yuan was calculated for the day, considering that 454.5 billion yuan in reverse repos matured [2] Social Welfare Initiatives - The Ministry of Finance announced increased subsidies and nationwide coordination of pension insurance, benefiting over 300 million elderly individuals [3] - The Ministry of Education plans to address the shortage of high school seats by constructing or renovating over 1000 quality high schools and aims for standardized construction of compulsory education schools within five years [3] Sector Performance - Pharmaceutical stocks showed strong performance, particularly in the CRO and innovative drug sectors, with companies like Angli Kang and ZHONGSHENG Pharmaceutical hitting the daily limit [3] - Banking stocks also saw gains, with Chengdu Bank and Nanjing Bank reaching historical highs during trading [3] Weight Loss Drug Sector - The WHO has been developing new guidelines for obesity prevention and treatment since 2022, which includes the clinical indications and applications of GLP-1 drugs, potentially standardizing their use in weight management [4] - The weight loss drug sector is gaining attention, with GLP-1 drugs expected to see increased application among weight loss populations [4] Company Insights - Hanyu Pharmaceutical is transitioning from a domestic to a global enterprise, planning to launch nearly 20 peptide and small nucleic acid drugs overseas in the next decade, focusing on weight loss and diabetes [7] - Zhongsheng Pharmaceutical has become the only domestic company with both COVID-19 and influenza innovative drugs, aiming to enhance its market position in respiratory medications [8] - Kexing Pharmaceutical is preparing for the domestic approval of a biosimilar of semaglutide by 2025 and is expanding its overseas business through strategic partnerships [9] - Yipin Hong is focusing on innovation, with promising clinical data for AR882, which has the potential to be a best-in-class product [9]

A股创新药板块持续活跃，众生药业、昂利康涨停，联化科技涨超9%，睿智医药、海辰药业、翰宇药 业等高开。 订阅A股涨停捉妖队 +订阅 订阅A股市场资讯 +订阅 ...

Market Performance - A-shares showed strong momentum with major indices rising, Shanghai Composite Index surpassed 3400 points, and ChiNext Index increased over 1% [1] - Hong Kong stocks also performed well, with the Hang Seng Index rising over 1% and returning above 24000 points, while the Hang Seng Tech Index surged nearly 3% [1] - Total market turnover reached approximately 1.31 trillion yuan, an increase of 135.5 billion yuan from the previous trading day [1] Innovative Drug Sector - The innovative drug concept stocks experienced significant gains, with the innovative drug index rising over 4% [2] - Notable stocks included Hai Chen Pharmaceutical, Rui Zhi Pharmaceutical, and others, with nearly 15 related stocks hitting the daily limit or rising over 10% [2] - Since mid-May, innovative drug stocks have shown strong performance, with some stocks like Lianhua Technology increasing nearly 115% in the last nine trading days [2] Industry Developments - The 2025 American Society of Clinical Oncology (ASCO) annual meeting highlighted the competitiveness of Chinese pharmaceutical companies in new drug development [3] - Financial policies introduced since May 7 aim to stabilize market expectations, with a focus on supporting leading pharmaceutical companies with strong dividends [3] Rare Earth Sector - The rare earth sector became active, with the rare earth permanent magnet concept index rising 3.45% [4] - The demand for medium and heavy rare earths is increasing due to the development of industries like robotics and electric vehicles [4] - Supply tightening and policy changes have led to a recovery in rare earth prices, with expectations for continued moderate price increases [5] Elderly Care Robotics - The elderly care robotics sector showed strong performance, with the humanoid robot concept index rising 0.76% [7] - The Ministry of Industry and Information Technology and the Ministry of Civil Affairs announced a pilot program for intelligent elderly care service robots from 2025 to 2027 [7] - The report emphasized the investment value of the robotics sector, highlighting various types of intelligent elderly care robots that cater to different needs [8]

Group 1: General Information - The research was conducted on Zhongshan Biovalley Pharmaceutical Co., Ltd. in the traditional Chinese medicine industry on June 9, 2025. The company was represented by board secretary Yang Wei and securities affairs representative Chen Zimin [1][2][8] - Participating research institutions included Ping An Securities Co., Ltd., Shenzhen Chuanghua Qisheng Consulting Co., Ltd., and Far East Horizon [2][9] Group 2: R & D Pipeline - The company has established a multi - mode R & D ecosystem, focusing on metabolic and respiratory diseases. It has 2 approved innovative drugs and multiple projects in clinical trials [14] - In metabolic diseases, ZSP1601 for MASH is in Phase IIb clinical trials. RAY1225 for type 2 diabetes and obesity has completed Phase II trials and is entering Phase III [14][23][24] - In respiratory diseases, oral anti - COVID drug Lairetrievir and anti - influenza drug Enlatavir have been approved. Enlatavir granules for children are in Phase II trials [14][15][16] Group 3: R & D Results - ZSP1601 showed potential in reducing liver inflammation and fibrosis in Ib/IIa trials, with results published in Nature Communications [14] - Lairetrievir's research results are published in top journals, and it is included in the expert consensus for COVID treatment [15] - Enlatavir outperformed placebo and Oseltamivir in Phase III trials, and Enlatavir granules showed positive results in Phase II trials for children [16][17][18] - RAY1225 significantly outperformed placebo in weight loss, blood sugar control, and improving cardiovascular - kidney - metabolic risk factors in Phase II trials [25][26][27] Group 4: Marketing Strategy - The company deepens marketing innovation in three dimensions: academic ecosystem construction, digital service upgrade, and key project implementation for Enlatavir sales [19] Group 5: Asset Impairment - In 2024, the company recorded total asset impairment losses of 546.68 million yuan, reducing net profit and equity by 484.10 million yuan. The main reasons were inventory, goodwill, intangible assets, and R & D project impairments [20] Group 6: Equity Redemption - The company redeemed 13.15% of the equity in its subsidiary Zhongshan Biovalley Innovation from other shareholders for 546 million yuan, increasing its stake to 74.26% [29][30] Group 7: Change of Fund Use - The company plans to change the use of 103.08 million yuan of unused raised funds for the "New Drug R & D Project" of its subsidiary Zhongshan Biovalley Innovation, subject to shareholder approval [30][31]

Core Viewpoint - The current "medication" market rally is distinct from previous ones, with leading gains concentrated in innovative pharmaceutical companies, particularly strong performance in the Hong Kong stock market [1][2] Group 1: Market Performance - On June 9, both Hong Kong and A-share innovative pharmaceutical sectors saw significant gains, with the Hang Seng Innovative Drug ETF rising by 4.08% and the Hong Kong Stock Connect Medical ETF increasing by 4.25% [3] - Notable individual stock performances included 3SBio (01530.HK) reaching a peak of 22.5 HKD, just shy of its historical high, and a 260% increase in its stock price since February [3] - The A-share innovative drug index rose by 31.5% and the Hong Kong innovative drug index surged by 61.54% since April 9, with several stocks doubling in value [4] Group 2: Catalysts for Growth - The surge in innovative drug stocks is attributed to multiple factors, including recent approvals for 11 innovative drugs from eight companies and promising clinical data for major diseases [5] - The upcoming 2025 ASCO annual meeting will feature 73 research studies from China, a 30% increase from the previous year [5] Group 3: Long-term Positive Factors - Many leading companies are approaching breakeven points, with significant revenue growth reported, particularly for Ascentage Pharma (332.31% growth) [7][8] - The overseas licensing deals have seen substantial increases, with a record-breaking deal of 6.05 billion USD for 3SBio's drug rights to Pfizer [9] - The overall licensing-out transactions in the innovative drug sector have surged, with 41 transactions in Q1 2024 alone, totaling 36.93 billion USD [9] Group 4: Policy Support - Recent policy changes are favorable for innovative drug companies, including optimized centralized procurement policies and increased support for innovative drugs in government reports [10] - The 2024 government work report includes 38 new innovative drugs in the medical insurance catalog, the highest ever, with plans for further optimization in 2025 [10] Group 5: Market Outlook - The valuation of the pharmaceutical sector remains relatively safe compared to other growth industries, with a current TTM P/E ratio of 27.1 times [11] - Some analysts suggest that the innovative drug sector is transitioning from following to leading in the global market, indicating a new era for domestic innovation [11] - However, there are concerns about potential short-term volatility due to rapid price increases and profit-taking by investors [11]

Group 1: Company Overview and R&D Pipeline - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has established a multi-modal and healthy R&D ecosystem focusing on metabolic diseases and respiratory diseases, with two innovative drug projects approved for market and several in clinical trials [1] - The innovative drug ZSP1601 for treating metabolic dysfunction-related fatty liver disease (MASH) has completed Phase Ib/IIa clinical trials, showing significant reduction in liver inflammation markers [3][15] - The oral antiviral drug Lurivon (brand name: Le Ru Ling®) received conditional approval in March 2023 and is included in the national medical insurance directory, providing affordable treatment options for patients [3] Group 2: Clinical Trial Results - ZSP1601 has shown potential in improving liver inflammation and fibrosis, with results published in Nature Communications [3][15] - The clinical trial for Lurivon demonstrated effectiveness and safety, particularly for elderly and patients with liver and kidney dysfunction, without requiring dosage adjustments [3] - The innovative drug Anglave (brand name: An Rui Wei®) has shown statistically significant improvement in flu symptom relief compared to placebo, with a median symptom relief time of 38.83 hours [4][8] Group 3: Financial and Asset Management - In 2024, the company recorded an asset impairment loss of CNY 546.68 million, impacting the net profit attributable to shareholders by CNY 484.10 million [12] - The company has made provisions for inventory and goodwill impairment losses totaling CNY 201.68 million due to market conditions and policy impacts [12][14] Group 4: Strategic Initiatives and Future Plans - The company plans to enhance its marketing strategy by integrating academic resources and building a network of experts in respiratory and infectious diseases [11] - The company has increased its stake in its subsidiary Zhongsheng Ruichuang to 74.26%, enhancing control over its operations and R&D capabilities [27] - A change in the use of raised funds has been proposed to accelerate the R&D of innovative drugs, specifically RAY1225 injection and Anglave granules [28][30]

沪指6月9日上涨0.43%，申万所属行业中，今日上涨的有30个，涨幅居前的行业为医药生物、农林牧 渔，涨幅分别为2.30%、1.72%。医药生物行业位居今日涨幅榜首位。跌幅居前的行业为食品饮料，跌 幅分别为0.43%。 资金面上看，两市主力资金全天净流入35.37亿元，今日有16个行业主力资金净流入，非银金融行业主 力资金净流入规模居首，该行业今日上涨1.20%，全天净流入资金27.81亿元，其次是医药生物行业，日 涨幅为2.30%，净流入资金为20.27亿元。 医药生物行业今日上涨2.30%，全天主力资金净流入20.27亿元，该行业所属的个股共475只，今日上涨 的有435只，涨停的有16只；下跌的有36只。以资金流向数据进行统计，该行业资金净流入的个股有251 只，其中，净流入资金超亿元的有5只，净流入资金居首的是华海药业，今日净流入资金2.78亿元，紧 随其后的是睿智医药、众生药业，净流入资金分别为2.48亿元、2.47亿元。医药生物行业资金净流出个 股中，资金净流出超亿元的有5只，净流出资金居前的有恒瑞医药、千红制药、博瑞医药，净流出资金 分别为2.88亿元、1.18亿元、1.07亿元。（数据宝） | ...

Group 1 - The assisted reproductive concept sector increased by 3.33%, ranking 10th among concept sectors, with 68 stocks rising, including Haichen Pharmaceutical which hit a 20% limit up, and others like Zhongsheng Pharmaceutical, Meinuo Pharmaceutical, and Shuanglu Pharmaceutical also reaching their limit up [1][2] - Notable gainers in the assisted reproductive sector included Xinghao Pharmaceutical, Shengnuo Biological, and Saiseng Pharmaceutical, which rose by 27.29%, 17.58%, and 6.08% respectively [1][6] - The sector saw a net inflow of 414 million yuan from main funds, with 31 stocks receiving net inflows, and 6 stocks exceeding 30 million yuan in net inflow, led by Zhongsheng Pharmaceutical with a net inflow of 247 million yuan [2][3] Group 2 - The top three stocks by net inflow ratio in the assisted reproductive sector were Zhongsheng Pharmaceutical at 55.08%, Shuanglu Pharmaceutical at 20.11%, and Meinuo Pharmaceutical at 17.33% [3][4] - The trading volume and turnover rates for leading stocks in the sector were significant, with Zhongsheng Pharmaceutical showing a daily increase of 9.99% and a turnover rate of 3.84% [3][4] - Other stocks with notable performance included Fuxing Pharmaceutical with a 3.60% increase and a turnover rate of 2.17%, and Meinuo Pharmaceutical with a 9.97% increase and a turnover rate of 7.37% [3][4]